title: Association between the pattern of IGFBP-1 alteration and the glucose/insulin metabolic control.
abstract: Little is known on the possible association between impaired glucose/insulin metabolism, the pattern of IGFBP-1 phosphorylation and the complex formation with other serum proteins. In this study, the concentration, isoform, multimer and complex pattern of IGFBP-1 was compared in healthy persons and patients with type 2 diabetes mellitus or with hypoglycemia. Concentrations of insulin and IGFBP-1 were determined by radioimmunoassay. Metal affinity and immunoaffinity chromatography were used for the separation of molecular forms of IGFBP-1, which were detected by immunoblotting and SELDI. The counter directional change in insulin and IGFBP-1 concentrations, expressed as a factor that takes into consideration the rate of insulin increase and IGFBP-1 decrease after glucose intake was approximately twice more pronounced in patients with diabetes than in healthy and hypoglycemic persons. The alteration in the phosphorylation pattern of IGFBP-1 due to diabetes or hypoglycemia was not observed. IGFBP-1 multimers found in the circulation of patients with diabetes type 2 differed from those detected in the circulation of others: there were 3 molecular forms between 90 and 100 kDa (compared to one in patients with hypoglycemia or 2 in healthy persons), 2 of which were α (2)M-reactive and one not. These results suggest a possible greater involvement of IGF system in glucose regulation in patients with diabetes type 2.
authors.affiliation: Institute for the Application of Nuclear Energy, University of Belgrade, Banatska 31b, Belgrade-Zemun, Serbia. olgica@inep.co.rs
authors.forename: O
authors.initials: O
authors.lastname: Nedić
authors.forename: R
authors.initials: R
authors.lastname: Masnikosa
authors.forename: D
authors.initials: D
authors.lastname: Lagundžin
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D016022:Case-Control Studies; D048909:Diabetes Complications / Q000097:blood / Q000175:diagnosis / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006262:Health; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000150:complications / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000032:analysis / Q000097:blood* / Q000737:chemistry / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D009994:Osmolar Concentration; D055503:Protein Multimerization
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; C032231:IGFBP1 protein, human; D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1